Go to main contentGo to footer
Dr. Stefano Pallanti

Credentials

Dr. Pallanti is recognized as one of the world's leading experts in Anxiety and Obsessive-Compulsive Disorders and has extensive experience in many other disorders including ADHD, Autism, Depression and Schizophrenia.

Dr. Pallanti serves on many distinguished boards and advisory councils and is the author of more than 400 peer-reviewed scientific publications,15 books, and 4 psychiatry manuals including the "Clinical Manual for Treatment of Schizophrenia" published by American Psychiatric Publishing. 

ADHD

Dr. Stefano Pallanti is leading experts for diagnosis and treatment of ADHD in adults.

In 2018, Dr. Stefano Pallanti established at Stanford University (CA, USA) the Adult ADHD Program applying "Precision Medicine." Back in 1998, Dr. Pallanti founded the first Adult ADHD Program in Europe.

He edited the Italian edition of the assessment tool for ADHD in adults: BAARS-IV (Barkley Adult ADHD Rating Scale-IV).

Dr. Pallanti is also the Italian referent of DIVA 2.0 (Diagnostic Interview for ADHD in Adults) and members of the European Adult ADHD Network.

Anxiety

Depression

  • Board member, European Commission consensus initiative on depression and its treatment (EU PEARL). 

  • Since 2005, Prof. Pallanti has been one of the world's pioneers in the use of Neuromodulation Therapies (Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation) for the clinical treatment of Depression and Anxiety.

Obsessive-Compulsive Disorder (OCD)

  • Dr. Pallanti is one of the leading experts on OCD in the world.

  • Board Member, International College of Obsessive-Compulsive Spectrum Disorders (ICOCS, UK).

  • For the European College of Neuropsychopharmacology (ECNP), Dr. Pallanti serves in several roles: Executive Committee Member (2016 – 2019), Obsessive-Compulsive and Related Disorders Network Member, Scientific Committee Board Member, Scientific Advisory Panel Member for Anxiety, Chair of the ECNP Neuromodulation Thematic Working Group.

  • From 2005 to 2007, Dr. Pallanti has held the positions of Member of the OCD Spectrum Workgroup, the Impulse Control Disorders Taskforce and the International Advisory Board of the American Psychiatric Association (APA) for DSM-5 (The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; Chair D.J. Kupfer).

  • Author of the chapter “Incompleteness and Harm Avoidance in OCD“ included in the handbook "Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment" published by Oxford University Press. ISBN-13:9780190228163. DOI:10.1093/med/9780190228163.001.0001.

Obsessive-Compulsive Disorder (OCD) in childhood and adolescence

  • International Expert of the German Association of Scientific Medical Associations on behalf of the German Society for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy (DGKJPP) for development of the interdisciplinary evidence- and consensus-based S3 Guideline for the diagnosis and treatment of obsessive-compulsive disorder in childhood and adolescence (interdisziplinäre evidenz- und konsensbasierte S3-Leitlinie für Diagnostik und Therapie von Zwangsstörungen im Kindes- und Jugendalter).

Attention-Deficit Hyperactivity Disorder (ADHD)

  • Dr. Pallanti started the first adult ADHD program in Europe in 1998 at the University of Florence's Careggi Hospital and at his private clinic.

  • He established the first "Applied Precision Medicine ADHD" program at Stanford University (California, USA), where he also worked as a TMS consultant. From 2017 to 2019, he was a Full Professor of Psychiatry and Behavioral Sciences.

  • Author of the book The Burden of Adult ADHD in Comorbid Psychiatric and Neurological Disorders published by Springers.

  • Editor of the BAARS-IV (Barkley Adult ADHD Rating Scale-IV) adult ADHD assessment tool, Italian version.

  • Referent of DIVA 2.0 (Diagnostic Interview for ADHD in Adults) in Italy

  • Member of the European Adult ADHD Network.

PANS – PANDAS

  • Member of PANDAS Physicians' Network.

  • Protocol Advisory Board of PACE Foundation (a non-profit organization dedicated to improving the diagnosis, treatment and quality of life of children with Pediatric Autoimmune Neurological Disorders).

Autism

  • Member of the Advisory Council of ICare4Autism (International Center for Autism Research and Education ― New York, USA)

  • Author of the scientific paper Transcranial Photobiomodulation for the Treatment of Children with Autism Spectrum Disorder (ASD): A Retrospective Study, Pallanti, S., Ponzio, M., Grassi, E., Vannini, G., Cauli, G. . Bambini 2022, 9, 755.

  • Author of the chapter "Pharmacological treatment of Autism Spectrum Disorders" in the handbook "Autism Spectrum Disorders- Phenotypes, Mechanisms and Treatment" edited by M. Leboyer, P. Chaste, published by Karger Medical and Scientific Publishers in 2015.

  • Author of “New Technologies in Autism: Non-invasive Brain Stimulation” in the handbook "Autism Spectrum Disorders" edited by E. Hollander, D. Fein, P.J. Hagerman, published by Karger Medical and Scientific Publishers in 2017.

  • Author of the chapter “Transcranial Magnetic Stimulation and Non-invasive Brain Stimulation” in the handbook "Autism Spectrum Disorders", edited by E. Hollander et al., published by American Psychiatric Association Publishing in 2018. ISBN 978-1-61537-052-8

  • Lecturer of the Level I Master's Degree "Percorsi nell'Autismo e disturbi pervasivi dello sviluppo dell'adulto", organized at the University of Florence in 2009-2010 in collaboration with: Società Italiana per lo Studio del Ritardo Mentale, Autismo Italia Onlus and Yale Child Study Center (Yale University).

Behavioral Addictions

Psychosis and Schizophrenia

  • Coauthor with Lauriello J. of Clinical Manual for Treatment of Schizophrenia published in 2012 by American Psychiatric Publishing. ASIN: B01K03HSGA

  • Author of the handbook "Oltre la Schizodrenia," published in 2015 by Edra. ISBN-10. 8821438546

Long COVID

  • Member of the COVID-19 Clinical Research Coalition's Ethics Working Group of WHO and the Good Clinical Practice Alliance (GCPA).